<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774019</url>
  </required_header>
  <id_info>
    <org_study_id>90914721</org_study_id>
    <secondary_id>E7059</secondary_id>
    <nct_id>NCT01774019</nct_id>
  </id_info>
  <brief_title>Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer</brief_title>
  <official_title>Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that preoperative biliary drainage using
      self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in
      patients undergoing pancreaticoduodenectomy for treatment of pancreatic or periampullary
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2013</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last</measure>
    <time_frame>120 days</time_frame>
    <description>Count of Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Adverse events will be assessed in terms of rate, severity, seriousness, relatedness to stent or endoscopic or surgical procedure, impact on time of surgery, length of hospitalization and ICU stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgery</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Days until subject undergoes surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Details related to Curative Intent Surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of intraoperative blood loss and number of blood transfusions, duration of surgery</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Intraoperative blood loss in ml, count of transfusions and time from start to finish of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biliary obstructive symptoms assessment</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <description>Record of symptoms associated with biliary obstruction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of liver function test (LFT) levels as relative to baseline</measure>
    <time_frame>Week 2 - 120 days</time_frame>
    <description>Laboratory tests for liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent placement success</measure>
    <time_frame>Procedure</time_frame>
    <description>Stent placement success: ability to deploy the stent in satisfactory position across the stricture (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent removal success</measure>
    <time_frame>At time of surgery or prior to surgery if re-intervention is needed.</time_frame>
    <description>Stent removal success: successful SEMS removal, either en bloc at time of surgery or endoscopically prior to surgery without stent removal related SAEs (For patients who are randomized to biliary drainage with a metal stent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number, type, reason, and timing of biliary re-interventions</measure>
    <time_frame>Baseline - 120 days</time_frame>
    <description>Count and timing of biliary re-interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Count of admissions to hospital and ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital and ICU admissions</measure>
    <time_frame>Procedure - 120 days</time_frame>
    <description>Length of stay in hospital and ICU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">294</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>None (No Pre-Operative Biliary Drainage)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this group will not receive pre-operative biliary drainage with a study SEMS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</intervention_name>
    <arm_group_label>WallFlex™ Biliary RX Fully Covered/Uncovered Stent System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Willing and able to comply with the study procedures and provide written informed
             consent to participate in the study

          -  Diagnosis of probable pancreatic cancer, distal common bile duct (CBD)
             cholangiocarcinoma and other periampullary cancers (histology not required)

          -  Biliary obstructive symptoms or signs

          -  Bilirubin level at/above 100 umol per liter (5.8 mg/dL)

          -  Distal biliary obstruction consistent with pancreatic cancer, distal CBD
             cholangiocarcinoma or other periampullary malignancy

          -  Location of distal biliary obstruction is such that it would allow the proximal end of
             a stent to be positioned at least 2cm from the hilum

          -  Patients deemed as resectable by pancreatic protocol CT or MRI

          -  Surgical candidate per pancreatobiliary surgeon after multi-disciplinary discussion

          -  Surgery intent within 4 weeks

          -  Endoscopic and surgical treatment to be provided by same team

        Exclusion Criteria:

          -  Biliary strictures caused by confirmed benign tumors

          -  Biliary strictures caused by malignancies other than pancreatic cancer, distal CBD
             cholangiocarcinoma and other periampullary cancers

          -  Surgically altered biliary tract anatomy, not including prior cholecystectomy

          -  Neoadjuvant chemotherapy for current malignancy

          -  Palliative indication due to reasons other than surgical candidate status

          -  Previous biliary drainage by ERCP/PTC

          -  Patients for whom endoscopic techniques are contraindicated

          -  Participation in another investigational trial within 90 days

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Costamagna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Burbage</last_name>
    <phone>508-683-4387</phone>
    <email>andrea.burbage@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Talia Romano</last_name>
    <phone>508-683-6132</phone>
    <email>talia.romano@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Standford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>ULB Erasme Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Persoons</last_name>
      <phone>+32 2 555 3016</phone>
      <email>Mia.Persoons@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Devière, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Yee Suen</last_name>
      <email>suenbingyee@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Nam-Hung Chia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, the Chinese University of Hong Kong</name>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Yee Suen</last_name>
      <email>suenbingyee@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>James Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asian Institute of Gastroenterology</name>
      <address>
        <city>Hyderabad</city>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Fatima</last_name>
      <email>sana.aigindia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nageshwar Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Gualtieri</last_name>
      <phone>+390630156580</phone>
      <email>carolina.gualtieri@policlinicogemelli.it</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Tringali, MD</last_name>
      <email>andrea.tringali@unicatt.it</email>
    </contact_backup>
    <investigator>
      <last_name>Guido Costamagna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic</keyword>
  <keyword>Periampullary Cancer</keyword>
  <keyword>Preoperative Biliary Drainage</keyword>
  <keyword>Resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

